Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | April 29, 2022 | May 03, 2022 |
| AbbVie Inc.ABBV · Entity 2800 | Director | May 09, 2025 | May 13, 2025 |
| CORNING INC /NYGLW · Entity 2883 | Former Director | April 26, 2012 | April 30, 2012 |
| Phillips 66PSX · Entity 2915 | Director | January 15, 2026 | January 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 29, 2022 · Filed May 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 46,128 |
Reported balance
After 2022-04-29 transaction · row 1
1 source rowRow 1 · 2022-04-29 · Grant · Acquired 1,602 · Balance 46,128 F1: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Wife | 350 |
Reported balance
Holding disclosure · report date 2022-04-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 350 F2: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: The reporting person disclaims beneficial ownership of all securities held by his spouse.
AbbVie Inc.
Report date May 09, 2025 · Filed May 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 51,564 |
Reported balance
After 2025-05-09 transaction · row 1
1 source rowRow 1 · 2025-05-09 · Grant · Acquired 1,203 · Balance 51,564 F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy wife | 350 |
Reported balance
Holding disclosure · report date 2025-05-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 350 F2: The reporting person disclaims beneficial ownership of all securities held by his wife. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: The reporting person disclaims beneficial ownership of all securities held by his wife.
CORNING INC /NY
Report date April 26, 2012 · Filed April 30, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,457 |
Reported balance
After 2012-04-26 transaction · row 1
1 source rowRow 1 · 2012-04-26 · Disposition to issuer · Disposed 5,943 · Balance 8,457 F1: Mr. Tilton left Corning's Board when his term expired and did not stand for re-election to Corning's Board at the end of his term. As a result, a prorated number of restricted stock shares from the February 1, 2012 grant were forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Tilton left Corning's Board when his term expired and did not stand for re-election to Corning's Board at the end of his term. As a result, a prorated number of restricted stock shares from the February 1, 2012 grant were forfeited.
Phillips 66
Report date January 15, 2026 · Filed January 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 74,437.0903 |
Reported balance
After 2026-01-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-15 · Grant · Acquired 1,423 · Balance 74,437.0903 F1: Annual grant to non-employee directors of Restricted Stock Units (RSUs) that convert to Phillips 66 common stock on a 1-for-1 basis. F2: The price reflected above is the average of the high and the low price of Phillips 66's stock on January 15, 2026. F3: Includes 37,997.0903 RSUs including shares acquired through routine dividend transactions that are exempt under Rule 16a-11. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual grant to non-employee directors of Restricted Stock Units (RSUs) that convert to Phillips 66 common stock on a 1-for-1 basis.
F2: The price reflected above is the average of the high and the low price of Phillips 66's stock on January 15, 2026.
F3: Includes 37,997.0903 RSUs including shares acquired through routine dividend transactions that are exempt under Rule 16a-11.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2026 Filed Jan 20, 2026 17:08 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 1,423 | $140.56 | $200,016.88 |
DisclosureSEC source: 0001194624-26-000002 · wk-form4_1768946910.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,437.0903 F1 · shares: Annual grant to non-employee directors of Restricted Stock Units (RSUs) that convert to Phillips 66 common stock on a 1-for-1 basis. F2 · price: The price reflected above is the average of the high and the low price of Phillips 66's stock on January 15, 2026. F3 · balance_after: Includes 37,997.0903 RSUs including shares acquired through routine dividend transactions that are exempt under Rule 16a-11. Read SEC document |
| May 09, 2025 Filed May 13, 2025 17:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-012803 · form4-05132025_050524.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,564 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 17:55 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 1,684 | $118.78 | $200,020.30 |
DisclosureSEC source: 0001534701-25-000024 · wk-form4_1737154542.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,618.2512 F1 · shares: Annual grant to non-employee directors of Restricted Stock Units (RSUs) that convert to Phillips 66 common stock on a 1-for-1 basis. F2 · price: The price reflected above is the average of the high and the low price of the Company's stock on January 15, 2025. F3 · balance_after: Includes 36,266.2512 RSUs including shares acquired through routine dividend transactions that are exempt under Rule 16a-11. Read SEC document |
| May 03, 2024 Filed May 7, 2024 18:30 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012520 · form4-05072024_060507.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,361 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 20:08 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 1,524 | $131.31 | $200,116.44 |
DisclosureSEC source: 0001534701-24-000023 · wk-form4_1705626524.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,775.6487 F1 · shares: Annual grant to non-employee directors of Restricted Stock Units (RSUs) that convert to Phillips 66 common stock on a 1-for-1 basis. F2 · price: The price reflected above is the average of the high and the low price of the Company's stock on January 16, 2024. F3 · balance_after: Includes RSUs, including additional shares acquired through routine dividend transactions that are exempt under Rule 16a-11. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 17:32 UTC | Phillips 66 PSX · Entity 2915 | OtherCommon Stock | 39.7557 | $92.02 | $3,658.15 |
DisclosureSEC source: 0001534701-23-000109 · wf-form4_168746955349319.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,209.7223 F1 · kind: Reflects the cancellation of certain previously reported Restricted Stock Units (RSUs). F2 · balance_after: Includes 35,402.7223 RSUs, including additional units acquired through routine dividend transactions that are exempt under Rule 16a-11. Read SEC document |
| May 05, 2023 Filed May 9, 2023 17:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007677 · form4-05092023_050501.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,039 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 28, 2023 Filed May 2, 2023 17:17 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionStock Equivalent Units · Derivative | 2,230 | $151.12 Strike: $151.12 | $336,997.60 |
DisclosureSEC source: 0001415889-23-007107 · form4-05022023_090519.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,700 Underlying: Common Stock · 2,230 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The cash equivalent of 2,230 AbbVie stock equivalent units in the Abbott account was paid to the director upon his retirement from Abbott's board on April 28, 2023. F2 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. F2 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. F2 · balance_after: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 18:21 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 1,929 | $103.69 | $200,008.37 |
DisclosureSEC source: 0001534701-23-000018 · wf-form4_167417047718514.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,876.1941 F1 · shares: Annual grant to non-employee directors of Restricted Stock Units (RSUs) that convert to Phillips 66 common stock on a 1-for-1 basis. The restrictions on the RSUs lapse after the retirement, disability or death of the non-employee director. F2 · price: The price reflected above is the average of the high and the low price of the Company's stock on January 17, 2023. F3 · balance_after: Includes 37,476.1941 RSUs, including additional units acquired through routine dividend transactions that are exempt under Rule 16a-11. Read SEC document |
| May 06, 2022 Filed May 9, 2022 17:14 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002932 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,589 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 29, 2022 Filed May 3, 2022 22:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004558 · form4-05032022_030518.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,128 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 16:57 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 22,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001534701-22-000086 · wf-form4_164703579805064.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,538.6031 F1 · shares: Pursuant to an Agreement and Plan of Merger dated October 26, 2021, each outstanding common unit of Phillips 66 Partners LP held by the reporting person was converted into the right to receive 0.500 shares of Phillips 66 common stock effective on March 9, 2022. F1 · price: Pursuant to an Agreement and Plan of Merger dated October 26, 2021, each outstanding common unit of Phillips 66 Partners LP held by the reporting person was converted into the right to receive 0.500 shares of Phillips 66 common stock effective on March 9, 2022. F2 · balance_after: Includes 34,138.6031 Restricted Stock Units (RSUs) that settle for shares of Phillips 66 common stock on a 1-for-1 basis, including additional units acquired through routine dividend transactions that are exempt under Rule 16a-11. The restrictions on RSUs lapse after the retirement, death or disability of the non-employee director. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 16:56 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 2,284 | $87.57 | $200,009.88 |
DisclosureSEC source: 0001534701-22-000006 · wf-form4_164262940112209.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,038.6031 F1 · shares: Annual grant to non-employee directors of Restricted Stock Units ("RSUs") that convert to Phillips 66 common stock on a 1-for-1 basis. The restrictions on the RSUs lapse on the retirement, disability or death of the non-employee director. F2 · price: The price reflected above is the average of the high and the low price of the Company's stock on January 14, 2022. F3 · balance_after: Includes 34,138.6031 RSUs, including additional units acquired through routine dividend transactions that are exempt under Rule 16a-11. T Read SEC document |
| May 07, 2021 Filed May 11, 2021 17:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005208 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,168 F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002165 · form4-04272021_040410.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,526 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 17:48 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 2,771 | $72.19 | $200,045.42 |
DisclosureSEC source: 0001534701-21-000025 · wf-form4_161118290637498.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,303.1322 F1 · shares: Annual grant to non-employee directors of Restricted Stock Units (RSUs) that convert to Phillips 66 common stock on a 1-for-1 basis. The restrictions on the RSUs lapse beginning three years after the date of grant, pursuant to an election made by the non-employee director. F2 · price: The price reflected above is the average of the high and the low price of the Company's stock on January 15, 2021. F3 · balance_after: Includes 30,403.1322 RSUs, including additional units acquired through routine dividend transactions that are exempt under Rule 16a-11. Read SEC document |
| May 08, 2020 Filed May 12, 2020 17:04 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005787 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,487 F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005190 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,027 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:50 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 1,907 | $104.92 | $200,072.91 |
DisclosureSEC source: 0001534701-20-000021 · wf-form4_157929779732522.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,102.8804 F1 · shares: Annual grant to non-employee directors of Restricted Stock Units (RSUs) that convert to Phillips 66 common stock on a 1-for-1 basis. The restrictions on the RSUs lapse after the retirement, disability or death of the non-employee director. F2 · price: The price reflected above is the average of the high and the low price of the Company's stock on January 15, 2020. F3 · balance_after: Includes 26,202.8804 RSUs, including additional units acquired through routine dividend transactions that are exempt under Rule 16a-11. Read SEC document |
| May 03, 2019 Filed May 7, 2019 16:55 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005674 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,154 F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005303 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,053 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 17:31 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 2,155 | $92.84 | $200,059.43 |
DisclosureSEC source: 0001534701-19-000016 · wf-form4_154776427829070.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,334.5598 F1 · shares: Annual grant to non-employee directors of restricted stock units (RSUs) that convert to Phillips 66 common stock on a 1-for-1 basis. The restrictions on the RSUs lapse after the retirement, disability or death of the non-employee director. F2 · price: The price reflected above is the average of the high and the low price of the Company's stock on January 15, 2019. F3 · balance_after: Includes 23,434.5598 RSUs, including additional units acquired through routine dividend transactions that are exempt under Rule 16a-1. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 14:30 UTC | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon Stock, $0.01 par value | 5,400 | $91.90 | $496,274.04 |
DisclosureSEC source: 0001179110-18-009131 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,735 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $91.86 to $92.09, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2018 Filed May 7, 2018 20:28 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 1,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006410 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,335 F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006032 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,812 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 17:42 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 1,923 | $104.03 | $200,049.69 |
DisclosureSEC source: 0001534701-18-000020 · wf-form4_151631532934307.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,657.3335 F1 · shares: Annual grant to non-employee directors of restricted stock units that convert to Phillips 66 common stock on a 1-for-1 basis. The restrictions on the RSUs lapse on the retirement, disability or death of the non-employee director. F2 · price: The price reflected above is the average of the high and the low price of the Company's stock on the date of the award. F3 · balance_after: Includes shares acquired through routine dividend transactions that are exempt under Rule 16a-1. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 578 | $57.07 | $32,986.46 |
DisclosureSEC source: 0001179110-18-000340 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,629 Underlying: Common shares · 578 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 17:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 387 | $96.71 Strike: $0.00 | $37,426.77 |
DisclosureSEC source: 0001179110-18-000327 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,229 Underlying: Common Stock · 387 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 21:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 618 | $53.36 | $32,976.48 |
DisclosureSEC source: 0001179110-17-013011 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,902 Underlying: Common shares · 618 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 16:32 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 422 | $88.86 Strike: $0.00 | $37,498.92 |
DisclosureSEC source: 0001179110-17-012954 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,503 Underlying: Common Stock · 422 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 678 | $48.61 | $32,957.58 |
DisclosureSEC source: 0001179110-17-010106 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,120 Underlying: Common shares · 678 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 11:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 517 | $72.51 Strike: $0.00 | $37,487.67 |
DisclosureSEC source: 0001179110-17-009956 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,970 Underlying: Common Stock · 517 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 2,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006930 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,436 F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006412 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,867 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 743 | $44.41 | $32,996.63 |
DisclosureSEC source: 0001179110-17-005582 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,265 Underlying: Common shares · 743 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 17:31 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 575 | $65.16 Strike: $0.00 | $37,467.00 |
DisclosureSEC source: 0001179110-17-005607 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,191 Underlying: Common Stock · 575 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 13:34 UTC | Phillips 66 PSX · Entity 2915 | GrantCommon Stock | 2,392 | $83.61 | $200,001.10 |
DisclosureSEC source: 0001534701-17-000014 · wf-form4_148476445198366.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,134.4027 F1 · security: Annual grant to non-employee directors of restricted stock units that convert to Phillips 66 common stock on a 1-for-1 basis. The restrictions on the RSUs lapse on the retirement, disability or death of the non-employee director. F1 · shares: Annual grant to non-employee directors of restricted stock units that convert to Phillips 66 common stock on a 1-for-1 basis. The restrictions on the RSUs lapse on the retirement, disability or death of the non-employee director. F2 · price: The price reflected above is the average of the high and the low price of the Company's stock on January 13, 2017. F3 · balance_after: Includes shares acquired through routine dividend transactions that are exempt under Rule 16a-1. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 859 | $38.41 Strike: $0.00 | $32,994.19 |
DisclosureSEC source: 0001179110-17-000267 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,351 Underlying: Common shares · 859 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 17:33 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 598 | $62.62 Strike: $0.00 | $37,446.76 |
DisclosureSEC source: 0001179110-17-000303 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,342 Underlying: Common Stock · 598 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 780 | $42.29 Strike: $0.00 | $32,986.20 |
DisclosureSEC source: 0001179110-16-030315 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,313 Underlying: Common shares · 780 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 17:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 594 | $63.07 Strike: $0.00 | $37,463.58 |
DisclosureSEC source: 0001179110-16-030342 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,512 Underlying: Common Stock · 594 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2016 Filed Jul 5, 2016 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 839 | $39.31 Strike: $0.00 | $32,981.09 |
DisclosureSEC source: 0001179110-16-027359 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,381 Underlying: Common shares · 839 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2016 Filed Jul 15, 2016 19:54 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 573 | $61.91 Strike: $0.00 | $35,474.43 |
DisclosureSEC source: 0001179110-16-027686 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,709 Underlying: Common Stock · 573 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| May 06, 2016 Filed May 10, 2016 17:25 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 2,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-024270 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,666 F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 29, 2016 Filed May 3, 2016 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-023684 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,430 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 31, 2016 Filed Apr 1, 2016 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 788 | $41.83 Strike: $0.00 | $32,962.04 |
DisclosureSEC source: 0001179110-16-022542 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,369 Underlying: Common shares · 788 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2016 Filed Apr 4, 2016 17:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 603 | $57.12 Strike: $0.00 | $34,443.36 |
DisclosureSEC source: 0001179110-16-022685 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,917 Underlying: Common Stock · 603 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2015 Filed Jan 5, 2016 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 734 | $44.91 Strike: $0.00 | $32,963.94 |
DisclosureSEC source: 0001179110-16-017080 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,413 Underlying: Common shares · 734 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2015 Filed Jan 5, 2016 17:14 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 582 | $59.24 Strike: $0.00 | $34,477.68 |
DisclosureSEC source: 0001179110-16-017102 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,067 Underlying: Common Stock · 582 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2015 Filed Oct 2, 2015 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 820 | $40.22 Strike: $0.00 | $32,980.40 |
DisclosureSEC source: 0001179110-15-013726 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,550 Underlying: Common shares · 820 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.